E. V. Privalova
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
E. V. Privalova has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Yuriy Nikitich Belenkov
Sechenov First Moscow State Medical University (Sechenov University)
12 shared publications - E. I. Tashina
First Moscow State Medical University named after I.M. Sechenov (Sechenov University), Moscow, Russian Federation
5 shared publications - V. Yu. Kaplunova
First Moscow State Medical University named after I.M. Sechenov (Sechenov University), Moscow, Russian Federation
5 shared publications - Gayane A. Shakaryants
First Moscow State Medical University named after I.M. Sechenov (Sechenov University), Moscow, Russian Federation
4 shared publications - Anastasiya Shchendrygina
Sechenov University
3 shared publications - E. Yu. Salakheeva
Sechenov First Moscow State Medical University
3 shared publications
Latest Publications
- 29 March 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (2)
Impact of microRNA-21 on the development of clinical variations and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy
Aim. To evaluate the impact of microRNA-21 expression levels on the development of clinical variants and risk of sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM). Material and methods. The study included 84 participants as follows: 42 patients (22 men and 20 women) with a confirmed diagnosis of HCM, and 42 patients without HCM, matched for sex and age (the control group). The mean age of the participants was 57,2±14,2 years. All participants underwent a comprehensive examination, including electrocardiography, echocardiography assessing hypertrophy and diastolic function parameters, Holter monitoring, and laboratory tests (including N-terminal probrain natriuretic peptide). For molecular biology analysis, circulating microRNA-21 levels in plasma were measured in all participants using real-time polymerase chain reaction. Results. MicroRNA-21 levels were significantly elevated in all patients with HCM compared to the control group (pConclusion. MicroRNA-21 is a sensitive biomarker of pathological myocardial remodeling in HCM but is not suitable for stratifying individual SCD risk. The increased risk of SCD in progressive cases is likely due to different substrate not directly reflected by this microRNA level. Risk stratification should remain comprehensive.
- 29 March 2026
- Published by Silicea - Poligraf, LLC in Russian Journal of Cardiology
- Vol. 31 (2)
Impact of microRNA-21 on the development of clinical variations and risk of sudden cardiac death in patients with hypertrophic cardiomyopathy
Aim. To evaluate the impact of microRNA-21 expression levels on the development of clinical variants and risk of sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM). Material and methods. The study included 84 participants as follows: 42 patients (22 men and 20 women) with a confirmed diagnosis of HCM, and 42 patients without HCM, matched for sex and age (the control group). The mean age of the participants was 57,2±14,2 years. All participants underwent a comprehensive examination, including electrocardiography, echocardiography assessing hypertrophy and diastolic function parameters, Holter monitoring, and laboratory tests (including N-terminal probrain natriuretic peptide). For molecular biology analysis, circulating microRNA-21 levels in plasma were measured in all participants using real-time polymerase chain reaction. Results. MicroRNA-21 levels were significantly elevated in all patients with HCM compared to the control group (pConclusion. MicroRNA-21 is a sensitive biomarker of pathological myocardial remodeling in HCM but is not suitable for stratifying individual SCD risk. The increased risk of SCD in progressive cases is likely due to different substrate not directly reflected by this microRNA level. Risk stratification should remain comprehensive.
- Open Access
- 11 February 2026
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 66 (1) , 31-37
Integrative Assessment of the Diagnostic Significance of the microRNA (-21, -29a, -133a) Panel in Patients With Hypertrophic Cardiomyopathy in Comparison With the Control Group
Aim : To evaluate the diagnostic significance of a microRNA panel (-21, -29a, -133a) in patients with hypertrophic cardiomyopathy (HCM) by comparing their expression levels to a group with moderate arterial hypertension (comparison group). Material and methods : A comparative study was conducted involving 80 individuals: 40 patients with confirmed HCM and 40 sex- and age-matched controls (22 men, 18 women, mean age 55.3±13.3 years). All participants underwent a comprehensive examination at the cardiology department, including electrocardiography (ECG), echocardiography with full assessment of intracardiac hemodynamic parameters, Holter ECG monitoring, and laboratory tests. For molecular biological analysis, plasma expression levels of circulating microRNAs (-21, -29a, -133a) were determined for all participants using real-time polymerase chain reaction. Results : Circulating microRNA levels differed significantly between patients with HCM and the comparison group. The analysis showed a significant increase in the microRNA-21 expression (4.07 v s . 2.03; p vs . 1.83; p vs . 6.34; p Conclusion : Increased expression of microRNA-21 and decreased expression of microRNA-29a are associated with myocardial fibrosis, while marked suppression of microRNA-133a reflects hypertrophic remodeling. These findings suggest that this microRNA panel holds promise as potential auxiliary markers for HCM, though clinical significance requires validation in larger, prospective studies.
- 11 February 2026
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 66 (1) , 31-37
Open AccessIntegrative Assessment of the Diagnostic Significance of the microRNA (-21, -29a, -133a) Panel in Patients With Hypertrophic Cardiomyopathy in Comparison With the Control Group
Aim : To evaluate the diagnostic significance of a microRNA panel (-21, -29a, -133a) in patients with hypertrophic cardiomyopathy (HCM) by comparing their expression levels to a group with moderate arterial hypertension (comparison group). Material and methods : A comparative study was conducted involving 80 individuals: 40 patients with confirmed HCM and 40 sex- and age-matched controls (22 men, 18 women, mean age 55.3±13.3 years). All participants underwent a comprehensive examination at the cardiology department, including electrocardiography (ECG), echocardiography with full assessment of intracardiac hemodynamic parameters, Holter ECG monitoring, and laboratory tests. For molecular biological analysis, plasma expression levels of circulating microRNAs (-21, -29a, -133a) were determined for all participants using real-time polymerase chain reaction. Results : Circulating microRNA levels differed significantly between patients with HCM and the comparison group. The analysis showed a significant increase in the microRNA-21 expression (4.07 v s . 2.03; p vs . 1.83; p vs . 6.34; p Conclusion : Increased expression of microRNA-21 and decreased expression of microRNA-29a are associated with myocardial fibrosis, while marked suppression of microRNA-133a reflects hypertrophic remodeling. These findings suggest that this microRNA panel holds promise as potential auxiliary markers for HCM, though clinical significance requires validation in larger, prospective studies.
- Open Access
- 31 January 2025
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 65 (1) , 58-66
The Structure of Concomitant Pathology in Patients With Hypertrophic Cardiomyopathy in The Older Age Group. Review and Clinical Observations
Advances in modern drug and surgical treatment of patients with hypertrophic cardiomyopathy (HCM) have resulted in a significant increase in the life expectancy of these extremely severe patients. Therefore, in addition to the genetic markers, major neurohumoral systems and morpho-functional parameters of intracardiac hemodynamics, the course and prognosis of the disease are influenced by concomitant pathology. In infancy and early childhood, HCM is associated with tumors of chromaffin tissue of various localizations; however, the older the patient, the greater the likelihood of developing metabolic syndrome, secondary atherosclerosis and ischemic heart disease (IHD), and hypertension, which significantly complicates the verification of the HCM diagnosis. We have previously described cases of IHD secondary to HCM, which significantly affected the course and prognosis of both diseases. However, in old age, other comorbidities may also occur in addition to the diseases described above. Based on long-term observation of a large cohort of patients, this article analyzes a wide range of HCM combinations with pathology of other organs and systems, including malignant neoplasms, which makes significant adjustments to the treatment of both the underlying disease and cancer. The material is presented in the form of a brief review of literature on this topic and our own clinical observations and studies.
- 31 January 2025
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 65 (1) , 58-66
Open AccessThe Structure of Concomitant Pathology in Patients With Hypertrophic Cardiomyopathy in The Older Age Group. Review and Clinical Observations
Advances in modern drug and surgical treatment of patients with hypertrophic cardiomyopathy (HCM) have resulted in a significant increase in the life expectancy of these extremely severe patients. Therefore, in addition to the genetic markers, major neurohumoral systems and morpho-functional parameters of intracardiac hemodynamics, the course and prognosis of the disease are influenced by concomitant pathology. In infancy and early childhood, HCM is associated with tumors of chromaffin tissue of various localizations; however, the older the patient, the greater the likelihood of developing metabolic syndrome, secondary atherosclerosis and ischemic heart disease (IHD), and hypertension, which significantly complicates the verification of the HCM diagnosis. We have previously described cases of IHD secondary to HCM, which significantly affected the course and prognosis of both diseases. However, in old age, other comorbidities may also occur in addition to the diseases described above. Based on long-term observation of a large cohort of patients, this article analyzes a wide range of HCM combinations with pathology of other organs and systems, including malignant neoplasms, which makes significant adjustments to the treatment of both the underlying disease and cancer. The material is presented in the form of a brief review of literature on this topic and our own clinical observations and studies.
- 30 November 2024
- Published by Technomed Holdings LLC in "Medical & Pharmaceutical Journal "Pulse"
PROGNOSTIC ROLE OF NEUROHUMORAL AND EPIGENETIC MARKERS IN THE FORMATION OF PHENOTYPIC MANIFESTATIONS OF HYPERTROPHIC CARDIOMYOPATHY
At the present time, the problem of studying hypertrophic cardiomyopathy (HCM) remains relevant due to the severity of this disease and the high risk of sudden cardiac death in the population, in particular in young and working age population, which can often be the first and only manifestation of this pathology. Consequently, the search for additional methods of early diagnosis and the development of tools for predicting the course of the disease remain priority areas of research in cardiology. Modern fundamental and clinical studies conducted all over the world are mostly focused on the search for relevant and accessible biomarkers in clinical practice of a doctor, among which special attention is paid to neurohumoral and epigenetic markers, which can be closely related to the possible outcome, the variant of the course of HCM in a patient, as well as can correlate with certain morphometric parameters according to the instrumental methods of examination and clinical picture, which in turn will later serve as a basis for a patient's personalised approach. These studies offer significant prospects for a patient personalised approach. Our review of the current literature on this topic is devoted to the analysis of current trends in cardiology, in particular, in the possible diagnosis and prognostic role of the course of HCM on the basis of neurohumoral and epigenetic markers. Particular attention is paid to the evaluation of the role of miR-29a and TGF-β 1 in patients with different variants of the course of HCM.
- 30 November 2024
- Published by Technomed Holdings LLC in "Medical & Pharmaceutical Journal "Pulse"
PROGNOSTIC ROLE OF NEUROHUMORAL AND EPIGENETIC MARKERS IN THE FORMATION OF PHENOTYPIC MANIFESTATIONS OF HYPERTROPHIC CARDIOMYOPATHY
At the present time, the problem of studying hypertrophic cardiomyopathy (HCM) remains relevant due to the severity of this disease and the high risk of sudden cardiac death in the population, in particular in young and working age population, which can often be the first and only manifestation of this pathology. Consequently, the search for additional methods of early diagnosis and the development of tools for predicting the course of the disease remain priority areas of research in cardiology. Modern fundamental and clinical studies conducted all over the world are mostly focused on the search for relevant and accessible biomarkers in clinical practice of a doctor, among which special attention is paid to neurohumoral and epigenetic markers, which can be closely related to the possible outcome, the variant of the course of HCM in a patient, as well as can correlate with certain morphometric parameters according to the instrumental methods of examination and clinical picture, which in turn will later serve as a basis for a patient's personalised approach. These studies offer significant prospects for a patient personalised approach. Our review of the current literature on this topic is devoted to the analysis of current trends in cardiology, in particular, in the possible diagnosis and prognostic role of the course of HCM on the basis of neurohumoral and epigenetic markers. Particular attention is paid to the evaluation of the role of miR-29a and TGF-β 1 in patients with different variants of the course of HCM.
- 30 November 2024
- Published by Technomed Holdings LLC in "Medical & Pharmaceutical Journal "Pulse"
DEVELOPMENT OF A PERSONALIZED TECHNIQUE FOR EARLY DIAGNOSIS AND PREDICTION OF VARIANTS OF THE COURSE OF HYPERTROPHIC CARDIOMYOPATHY BASED ON THE ANALYSIS OF MICRORNAS-21, 29A, 133A
For many years, cardiovascular diseases have occupied and continue to occupy leading positions due to mortality and disability of the adult working-age population. Hypertrophic cardiomyopathy (HCM) is the most common variant of cardiomyopathy, its prevalence among the general population worldwide is 0.2% (1 in 500 adults). The study of the disease has been taking place for quite a long time, the half-century history of studying the problem of HCMP reflects a significant evolution of knowledge in matters of etiology, pathogenesis, diagnosis, clinical course and prognosis, variants of the course of the disease, however, there are still no methods of early diagnosis that could be used as a possible screening of this condition in the early stages and forecasting its more severe course. New methods could make it possible to diagnose this condition at an early stage and predict a possible course of its course, thereby preventing such a formidable complication as sudden cardiac death (SCD). At the moment, there is a prediction model (HCM Risk-SCD) for the risk of SCD, based on the results of instrumental research methods and anamnesis data of a particular patient, but this model is not perfect enough, and therefore it is gaining great popularity and the search for various biomarkers continues based on well-known scientific achievements in the field of genomics and transcriptomics. Perhaps in the near future, the study of the levels of certain microRNAs, which have already proven their affinity for the degree of myocardial hypertrophy, will become a new milestone in the study of hypertrophic cardiomyopathy.
- 30 November 2024
- Published by Technomed Holdings LLC in "Medical & Pharmaceutical Journal "Pulse"
DEVELOPMENT OF A PERSONALIZED TECHNIQUE FOR EARLY DIAGNOSIS AND PREDICTION OF VARIANTS OF THE COURSE OF HYPERTROPHIC CARDIOMYOPATHY BASED ON THE ANALYSIS OF MICRORNAS-21, 29A, 133A
For many years, cardiovascular diseases have occupied and continue to occupy leading positions due to mortality and disability of the adult working-age population. Hypertrophic cardiomyopathy (HCM) is the most common variant of cardiomyopathy, its prevalence among the general population worldwide is 0.2% (1 in 500 adults). The study of the disease has been taking place for quite a long time, the half-century history of studying the problem of HCMP reflects a significant evolution of knowledge in matters of etiology, pathogenesis, diagnosis, clinical course and prognosis, variants of the course of the disease, however, there are still no methods of early diagnosis that could be used as a possible screening of this condition in the early stages and forecasting its more severe course. New methods could make it possible to diagnose this condition at an early stage and predict a possible course of its course, thereby preventing such a formidable complication as sudden cardiac death (SCD). At the moment, there is a prediction model (HCM Risk-SCD) for the risk of SCD, based on the results of instrumental research methods and anamnesis data of a particular patient, but this model is not perfect enough, and therefore it is gaining great popularity and the search for various biomarkers continues based on well-known scientific achievements in the field of genomics and transcriptomics. Perhaps in the near future, the study of the levels of certain microRNAs, which have already proven their affinity for the degree of myocardial hypertrophy, will become a new milestone in the study of hypertrophic cardiomyopathy.
- 30 September 2022
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 62 (9) , 3-8
The Prognostic Value of Neuregulin-1β in Heart Failure Patients With Preserved Ejection Fraction
Aim To determine the neuregulin-1β concentration in patients with chronic heart failure with preserved ejection fraction (HFpEF) and the association of this biomarker with the functional status of patients, echocardiographic parameters of the structural and functional condition of the heart, and the risk of unfavorable outcome. Material and methods This observational, prospective study included 47 patients with HFpEF; 32 (68%) of them were females. Mean age was 70 [66–77] years, EF was 57 [56; 58] %. The group of healthy volunteers consisted of 40 people; 32 (55 %) of them were females; mean age was 56 [53–61] years. For all patients, the functional status was evaluated (6-min walk test, 6MWT); standard echocardiography (EchoCG) was performed; and concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP) and neuregulin-1β were measured. The follow-up period was two years. Cases of cardiovascular (CV) death and hospitalizations for decompensated chronic heart failure (CHF) were recorded. Results Median concentration of neuregulin-1β was 0.969 [0.348; 1.932] ng/ml in the HFpEF group, which was significantly higher than 0.379 [0.195; 0.861] ng/ml in the group of healthy volunteers (р=0.003). Significant correlations between the neuregulin-1β concentration and the distance walked in 6MWT or with EchoCG parameters of left ventricular diastolic function were not found. Mean observation time was 456 [244; 730] days. 21 outcomes were observed, including 2 CV deaths and 19 hospitalizations for CHF. Patients with high concentrations of neuregulin-1β (≥Me) had a greater frequency of hospitalizations for CHF (Log-rank, p=0.046) and a higher risk of this outcome (risk ratio, 1.30; 95 % confidence interval, 1.01–1.66; p=0.037). Conclusion Patients with HFpEF had increased concentrations of neuregulin-1β. High levels of neuregulin-1β were associated with a higher risk of hospitalization for decompensated CHF.
- 30 September 2022
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 62 (9) , 3-8
The Prognostic Value of Neuregulin-1β in Heart Failure Patients With Preserved Ejection Fraction
Aim To determine the neuregulin-1β concentration in patients with chronic heart failure with preserved ejection fraction (HFpEF) and the association of this biomarker with the functional status of patients, echocardiographic parameters of the structural and functional condition of the heart, and the risk of unfavorable outcome. Material and methods This observational, prospective study included 47 patients with HFpEF; 32 (68%) of them were females. Mean age was 70 [66–77] years, EF was 57 [56; 58] %. The group of healthy volunteers consisted of 40 people; 32 (55 %) of them were females; mean age was 56 [53–61] years. For all patients, the functional status was evaluated (6-min walk test, 6MWT); standard echocardiography (EchoCG) was performed; and concentrations of N-terminal pro-brain natriuretic peptide (NT-proBNP) and neuregulin-1β were measured. The follow-up period was two years. Cases of cardiovascular (CV) death and hospitalizations for decompensated chronic heart failure (CHF) were recorded. Results Median concentration of neuregulin-1β was 0.969 [0.348; 1.932] ng/ml in the HFpEF group, which was significantly higher than 0.379 [0.195; 0.861] ng/ml in the group of healthy volunteers (р=0.003). Significant correlations between the neuregulin-1β concentration and the distance walked in 6MWT or with EchoCG parameters of left ventricular diastolic function were not found. Mean observation time was 456 [244; 730] days. 21 outcomes were observed, including 2 CV deaths and 19 hospitalizations for CHF. Patients with high concentrations of neuregulin-1β (≥Me) had a greater frequency of hospitalizations for CHF (Log-rank, p=0.046) and a higher risk of this outcome (risk ratio, 1.30; 95 % confidence interval, 1.01–1.66; p=0.037). Conclusion Patients with HFpEF had increased concentrations of neuregulin-1β. High levels of neuregulin-1β were associated with a higher risk of hospitalization for decompensated CHF.
- Open Access
- 12 January 2022
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 17 (6) , 853-859
Plasma Level’s of Neuregulin-1 in Healthy People
Aim. To determine the median levels of neuregulin-1 (NRG-1; endothelium-derived growth factor and the natural agonist of the ERBB3 and ERBB4 receptors) NRG-1 in healthy volunteers and to study the associations of NRG-1 levels with gender and age.Material and Methods. Ninety seven healthy participants were enrolled (median age of 44 [32-54], men 45 men [46.4%]). The following age groups were identified: 20-29 y.о. (n=20, men – 50.0%), 30-39 y.о. (n=21, men – 52.4%), 40-49 y.о. (n=22, men – 45.5%), 50-59 y.о. (n=22, men – 36.4%); 60-69 y.о. (n=12, men – 50.0%). Peripheral blood samples were collected at the time of enrolment, standard laboratory tests were performed, and NRG-1 levels were determined in the plasma samples by ELISA.Results. In the cohort of 97 healthy participants the median value of NRG-1 was 0.3 [0.121-2.24] ng/ml. NRG-1 levels did not differ significantly between men and women (p=0.145), indicating that NRG-1 levels are not influenced by gender. The levels of NRG-1 were similar in the different age groups: age 20-29 years=0.26 [0.17-0.37] ng/ml; age 30-39=0.24 [0.1-0.39] ng/ml; age 40-49=0.31 [0.19-1.15] ng/ml; age 50-59=0.37 [0.19-1.0] ng/ml; age 60-69=0.4 [0.13-0.81] ng/ml. Correlation analysis between NRG-1 levels and route blood measurements (haemoglobin, lipids, glucose, creatinine, and uretic acid) did not show significant associations.Conclusions. In this study, the median value of NRG-1 plasma levels were determined. The results of the study show that age and gender had no influence on NRG-1 values.
- 12 January 2022
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 17 (6) , 853-859
Open AccessPlasma Level’s of Neuregulin-1 in Healthy People
Aim. To determine the median levels of neuregulin-1 (NRG-1; endothelium-derived growth factor and the natural agonist of the ERBB3 and ERBB4 receptors) NRG-1 in healthy volunteers and to study the associations of NRG-1 levels with gender and age.Material and Methods. Ninety seven healthy participants were enrolled (median age of 44 [32-54], men 45 men [46.4%]). The following age groups were identified: 20-29 y.о. (n=20, men – 50.0%), 30-39 y.о. (n=21, men – 52.4%), 40-49 y.о. (n=22, men – 45.5%), 50-59 y.о. (n=22, men – 36.4%); 60-69 y.о. (n=12, men – 50.0%). Peripheral blood samples were collected at the time of enrolment, standard laboratory tests were performed, and NRG-1 levels were determined in the plasma samples by ELISA.Results. In the cohort of 97 healthy participants the median value of NRG-1 was 0.3 [0.121-2.24] ng/ml. NRG-1 levels did not differ significantly between men and women (p=0.145), indicating that NRG-1 levels are not influenced by gender. The levels of NRG-1 were similar in the different age groups: age 20-29 years=0.26 [0.17-0.37] ng/ml; age 30-39=0.24 [0.1-0.39] ng/ml; age 40-49=0.31 [0.19-1.15] ng/ml; age 50-59=0.37 [0.19-1.0] ng/ml; age 60-69=0.4 [0.13-0.81] ng/ml. Correlation analysis between NRG-1 levels and route blood measurements (haemoglobin, lipids, glucose, creatinine, and uretic acid) did not show significant associations.Conclusions. In this study, the median value of NRG-1 plasma levels were determined. The results of the study show that age and gender had no influence on NRG-1 values.
- Open Access
- 28 November 2021
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 20 (7) , 2923
Cardiovascular toxicity of antitumor therapy: effect on myocardial and vascular remodeling
Aim. To study the effect of multiagent chemotherapy on structural and functional vascular, electrophysiological parameters and cardiac hemodynamics in patients with stomach cancer.Material and methods. The study included 3 groups of 25 people: healthy volunteers, those with established cardiac disease (hypertension + coronary artery disease), gastric adenocarcinoma (fluoropyrimidine/platinum-based chemotherapy). Cancer patients before and after chemotherapy courses underwent non-invasive assessment of vascular wall and endothelial dysfunction (videocapillaroscopy, digital photoplethysmography), as well as electrocardiography and echocardiography. Healthy volunteers and cardiac patients were examined once.Results. In cancer patients, even before chemotherapy courses, endothelial dysfunction (ED) (occlusal index, 1,7 (1,4; 1,9), normal values >1,8) and structural vascular disorders (stiffness index, 8,9 m/s (7,7; 9,7), normal values Conclusion. The study for the first time assessed the effect of multiagent chemotherapy on ED, vascular stiffness and cardiac hemodynamics in patients with gastric cancer. A significant aggravation of all endothelial function parameters after treatment has been proven, which requires further study in order to develop criteria for early cardiovascular toxicity.
- 28 November 2021
- Published by Silicea - Poligraf, LLC in Cardiovascular Therapy and Prevention
- Vol. 20 (7) , 2923
Open AccessCardiovascular toxicity of antitumor therapy: effect on myocardial and vascular remodeling
Aim. To study the effect of multiagent chemotherapy on structural and functional vascular, electrophysiological parameters and cardiac hemodynamics in patients with stomach cancer.Material and methods. The study included 3 groups of 25 people: healthy volunteers, those with established cardiac disease (hypertension + coronary artery disease), gastric adenocarcinoma (fluoropyrimidine/platinum-based chemotherapy). Cancer patients before and after chemotherapy courses underwent non-invasive assessment of vascular wall and endothelial dysfunction (videocapillaroscopy, digital photoplethysmography), as well as electrocardiography and echocardiography. Healthy volunteers and cardiac patients were examined once.Results. In cancer patients, even before chemotherapy courses, endothelial dysfunction (ED) (occlusal index, 1,7 (1,4; 1,9), normal values >1,8) and structural vascular disorders (stiffness index, 8,9 m/s (7,7; 9,7), normal values Conclusion. The study for the first time assessed the effect of multiagent chemotherapy on ED, vascular stiffness and cardiac hemodynamics in patients with gastric cancer. A significant aggravation of all endothelial function parameters after treatment has been proven, which requires further study in order to develop criteria for early cardiovascular toxicity.
- Open Access
- 13 July 2021
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 17 (3) , 476-483
Heart Failure with Perserved Ejection Fraction Current Diagnostic and Therapeutic Approaches
Heart failure with preserved ejection fraction (HFpEF) is a syndrome associated with high morbidity and mortality rates. Little progress has been in the treatment of this condition since its introduction some 30 years ago. It's accepted that HFpEF is heterogeneous in many ways, ethologically and phenotypically. The underlying mechanisms of the syndrome are not clear. Recently, it has been shown that the diagnostic criteria for HFpEF lacks sensitivity and specificity. Novel treatment approaches, which were developed based on current HFpEF pathophysiological concepts, did not show either clinical or prognostic benefit for patients. Therefore, there is an urgent need to revise current diagnostic approaches and to further investigate the underlying mechanisms. Recently, two novel diagnostic score systems were proposed: H2PEF and HFA-PEFF. Recently, a number of phase II and III randomized control trials have been completed. Here, the authors discuss the potential novel diagnostic approaches to HFpEF and treatment perspectives.
- 13 July 2021
- Published by Silicea - Poligraf in Rational Pharmacotherapy in Cardiology
- Vol. 17 (3) , 476-483
Open AccessHeart Failure with Perserved Ejection Fraction Current Diagnostic and Therapeutic Approaches
Heart failure with preserved ejection fraction (HFpEF) is a syndrome associated with high morbidity and mortality rates. Little progress has been in the treatment of this condition since its introduction some 30 years ago. It's accepted that HFpEF is heterogeneous in many ways, ethologically and phenotypically. The underlying mechanisms of the syndrome are not clear. Recently, it has been shown that the diagnostic criteria for HFpEF lacks sensitivity and specificity. Novel treatment approaches, which were developed based on current HFpEF pathophysiological concepts, did not show either clinical or prognostic benefit for patients. Therefore, there is an urgent need to revise current diagnostic approaches and to further investigate the underlying mechanisms. Recently, two novel diagnostic score systems were proposed: H2PEF and HFA-PEFF. Recently, a number of phase II and III randomized control trials have been completed. Here, the authors discuss the potential novel diagnostic approaches to HFpEF and treatment perspectives.
- Open Access
- 11 February 2021
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 61 (1) , 52-58
Endothelial dysfunction and inflammation in patients with non-obstructive coronary arteries
Aim To determine levels of markers for endothelial dysfunction and inflammation, endothelin-1, E-selectin, and tumor necrosis factor α (TNF-α) in patients with ischemic heart disease (IHD) and non-obstructive and obstructive coronary artery (CA) disease. Material and methods This study included 32 patients with verified IHD and non-obstructive (main group, n=19) and obstructive (comparison group, n=13) CA disease. Endothelial dysfunction was diagnosed by photoplethysmography and videocapillaroscopy. Serum concentrations of endothelin-1, E-selectin, and TNF- α were measured in all patients. Results Patients with non-obstructive CA disease showed a tendency towards more pronounced endothelial dysfunction (alternative stiffness index, 7.8 m /s [6.35; 9.08]; reflection index, 36.95 % [23.4; 52.65]; capillary density following reactive hyperemia, 54.33 cap /mm2 [48.92; 75.83]; capillary density following venous occlusion, 74.33 cap /mm2 [67.83; 93.00]) compared to the comparison group (alternative stiffness index, 9.05 m/s [7.08; 10.58]; reflection index, 28.25 % [23.35; 53.75]; capillary density following reactive hyperemia, 66.83 cap /mm2 [50.83; 78.67]; capillary density following venous occlusion, 87.0 cap /mm2 [77.58; 78.67]), although statistically significant differences were not found. Concentration of endothelin-1 was significantly higher in the IHD group with non-obstructive CA disease (0.45 ng/ml [0.28;0.65]) compared to patients with CA atherosclerotic stenosis (0.35 ng/ml [0.25; 0.38], p=0.035). Concentrations of E-selectin did not significantly differ between the groups (main group, 21.1 ng/ml [18.45; 35.03]; comparison group, 28.55 ng/ml [19.08; 35.01], p=0.29). In both groups, concentrations of TNF-α did not exceed the lower threshold of sensitivity (Conclusion Endothelial dysfunction and increased endothelin-1 in patients with non-obstructive CA disease along with inflammation may additionally contribute to the pathogenesis of IHD in the absence of hemodynamically significant CA stenoses. Too low level of TNFα in both groups prevented us from using it as a diagnostic marker. Further study is needed that would include a greater number of patients and a search for alternative markers.
- 11 February 2021
- Published by APO Society of Specialists in Heart Failure in Kardiologiia
- Vol. 61 (1) , 52-58
Open AccessEndothelial dysfunction and inflammation in patients with non-obstructive coronary arteries
Aim To determine levels of markers for endothelial dysfunction and inflammation, endothelin-1, E-selectin, and tumor necrosis factor α (TNF-α) in patients with ischemic heart disease (IHD) and non-obstructive and obstructive coronary artery (CA) disease. Material and methods This study included 32 patients with verified IHD and non-obstructive (main group, n=19) and obstructive (comparison group, n=13) CA disease. Endothelial dysfunction was diagnosed by photoplethysmography and videocapillaroscopy. Serum concentrations of endothelin-1, E-selectin, and TNF- α were measured in all patients. Results Patients with non-obstructive CA disease showed a tendency towards more pronounced endothelial dysfunction (alternative stiffness index, 7.8 m /s [6.35; 9.08]; reflection index, 36.95 % [23.4; 52.65]; capillary density following reactive hyperemia, 54.33 cap /mm2 [48.92; 75.83]; capillary density following venous occlusion, 74.33 cap /mm2 [67.83; 93.00]) compared to the comparison group (alternative stiffness index, 9.05 m/s [7.08; 10.58]; reflection index, 28.25 % [23.35; 53.75]; capillary density following reactive hyperemia, 66.83 cap /mm2 [50.83; 78.67]; capillary density following venous occlusion, 87.0 cap /mm2 [77.58; 78.67]), although statistically significant differences were not found. Concentration of endothelin-1 was significantly higher in the IHD group with non-obstructive CA disease (0.45 ng/ml [0.28;0.65]) compared to patients with CA atherosclerotic stenosis (0.35 ng/ml [0.25; 0.38], p=0.035). Concentrations of E-selectin did not significantly differ between the groups (main group, 21.1 ng/ml [18.45; 35.03]; comparison group, 28.55 ng/ml [19.08; 35.01], p=0.29). In both groups, concentrations of TNF-α did not exceed the lower threshold of sensitivity (Conclusion Endothelial dysfunction and increased endothelin-1 in patients with non-obstructive CA disease along with inflammation may additionally contribute to the pathogenesis of IHD in the absence of hemodynamically significant CA stenoses. Too low level of TNFα in both groups prevented us from using it as a diagnostic marker. Further study is needed that would include a greater number of patients and a search for alternative markers.